
AstraZeneca mulling a $10-billion bid for Medivation – report
pharmafile | July 12, 2016 | News story | Manufacturing and Production, Sales and Marketing |Â Â AstraZeneca, Celgene, Medivation, Pfizer, Xtandi, cancer drug, merger and acquisitionÂ
Anglo Swedish drug firm AstraZeneca (LSE: AZN) is considering a $10-billion takeover bid for Medivation (Nasdaq: MDVN), according to reports.
The company is said to have revived its interest in the Maker of prostate cancer drug Xtandi (enzalutamide) and potentially looking to join the fray.
Medivation has a promising pipeline of cancer drugs making it an attractive target for big pharma firms looking to bolster their portfolio amidst shrinking profits.
Last week, Medivation rejected a raised takeover offer from Sanofi of $58 a share in cash. Medivation has also disclosed that it signed confidentiality agreements regarding a potential transaction with several companies, including the French drugmaker.
Reports have also indicated to US pharma giant Pfizer’s (NYSE: PFE) interest in Medivation for a potential takeover. Pfizer, as well as biotech firm Celgene (Nasdaq: CELD), are rumoured to be among the companies to have signed confidentially agreements with Medivation.
Anjali Shukla
Related Content

AstraZeneca’s Trixeo approved in EU for asthma
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a …

NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …






